Maria Cuce
Overview
Explore the profile of Maria Cuce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santo G, Cuce M, Restuccia A, Del Giudice T, Tassone P, Cicone F, et al.
Cancer Imaging
. 2024 Sep;
24(1):125.
PMID: 39289716
Background: Direct comparisons between [F]FDG PET/CT findings and clinical occurrence of immune-related adverse events (irAEs) based on independent assessments of clinical and imaging features in patients receiving immune checkpoint inhibitors...
2.
Staropoli N, Scionti F, Farenza V, Falcone F, Luciano F, Renne M, et al.
Biomed Pharmacother
. 2024 Mar;
174:116478.
PMID: 38547766
Background: Long-term survival induced by anticancer treatments discloses emerging frailty among breast cancer (BC) survivors. Trastuzumab-induced cardiotoxicity (TIC) is reported in at least 5% of HER2+BC patients. However, TIC mechanism...
3.
Staropoli N, Arbitrio M, Salvino A, Scionti F, Ciliberto D, Ingargiola R, et al.
Biomedicines
. 2022 May;
10(5).
PMID: 35625946
Carboplatin is the cornerstone of ovarian cancer (OC) treatment, while platinum-response, dependent on interindividual variability, is the major prognostic factor for long-term outcomes. This retrospective study was focused on explorative...
4.
Limongi T, Dattola E, Botta C, Coluccio M, Candeloro P, Cuce M, et al.
Front Bioeng Biotechnol
. 2020 Mar;
8:84.
PMID: 32117950
Polycaprolactone (PCL) is a biocompatible and biodegradable polymer widely used for the realization of 3D scaffold for tissue engineering applications. The hot embossing technique (HE) allows the obtainment of PCL...
5.
Cuce M, Gallo Cantafio M, Siciliano M, Riillo C, Caracciolo D, Scionti F, et al.
J Hematol Oncol
. 2019 Mar;
12(1):32.
PMID: 30898137
Background: Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damaging response (DDR) has an established role in disease pathobiology. Indeed, a deregulation of DNA repair...
6.
Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cuce M, Grillone F, et al.
Crit Rev Oncol Hematol
. 2018 Oct;
131:83-89.
PMID: 30293710
Introduction: Carboplatin is the milestone of epithelial ovarian cancer (EOC) treatment, thus response to platinum is the major prognostic factor. Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2...
7.
Botta C, Ciliberto D, Rossi M, Staropoli N, Cuce M, Galeano T, et al.
Blood Adv
. 2018 Jan;
1(7):455-466.
PMID: 29296961
Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory multiple myeloma (RRMM) remains a challenge; the rational choice of the most appropriate regimen in this setting is...
8.
Botta C, Cuce M, Caracciolo D, Fiorillo L, Tagliaferri P, Tassone P
Curr Cancer Drug Targets
. 2017 Apr;
17(9):819-838.
PMID: 28359248
Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM...